These Were the 10 Best Stocks of 2019
Seven biotechs led the way.
ArQule
ARQL
ARQL
$20.00
Price as of January 14, 2020, 7:00 p.m. EST
View Interactive ARQL Charts
A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.
Interactive Chart
News & Analysis: ArQule
Why Biotech Stock ArQule Soared 108% in December
This cancer-drug developer received a buyout offer from a big pharmaceutical company.
These Were the 10 Best Healthcare Stocks of 2019
Helping people stricken with illness can be richly rewarding in more ways than one.
What Happened in the Stock Market Today
Two big deals for cancer drug companies made news today. Merck plans to buy ArQule and Sanofi will pay up to buy Synthorx.
Why ArQule Shares Are Skyrocketing Today
A $2.7 billion buyout offer is causing this biotech stock to take off.
3 Biotech Stocks With a Lot to Prove at ASH 2019
These companies have some important presentations scheduled for the last big oncology conference of the year.
3 Soaring Biotech Stocks to Watch in December
Here's how they could keep on rocketing higher.
Here's Why ArQule Fell as Much as 28.3% Today
An update from an ongoing clinical trial appears to have disappointed investors, but that's not actually warranted by the data.
Arqule Inc (ARQL) Q3 2019 Earnings Call Transcript
ARQL earnings call for the period ending September 30, 2019.
ArQule: Buy the Dip?
The pharma company has wowed investors with solid clinical data multiple times this year.
